BID | 9.10 | ASK | 9.82 | ||
Open | 10.12 | Previous Close | 10.11 | ||
Pre-Market | - | After-Market | 9.77 | ||
- - | 0.02 0.21% |
Target Price | 13.63 | Analyst Rating | Moderate Buy 1.57 | |
Potential % | 39.79 | Finscreener Ranking | ★★★ 49.76 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 49.90 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★+ 40.97 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 28.70 | Earnings Rating | — | |
Market Cap | 717.93M | Earnings Date | 4th Oct 2023 | |
Alpha | -0.02 | Standard Deviation | 0.21 | |
Beta | 1.81 |
Today's Price Range 9.7310.21 | 52W Range 6.8317.01 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Neutral |
Performance | |||
---|---|---|---|
1 Week | - | ||
1 Month | - | ||
3 Months | - | ||
6 Months | - | ||
1 Year | - | ||
3 Years | -73.90% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -31.84 | |||
ROE last 12 Months | -71.05 | |||
ROA (5Y Avg) | -6.44 | |||
ROA last 12 Months | -39.92 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -43.33 | |||
Return on invested Capital Q | -5.52 | |||
Return on invested Capital Y | -15.29 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 12.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.30 | ||||
1.06 | ||||
2.09 | ||||
- | ||||
-14.40 | ||||
-0.84 | ||||
127.96 | ||||
7.04 | ||||
523.27M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.20 | ||||
3.30 | ||||
0.38 | ||||
0.63 | ||||
-166.10 | ||||
Leverage Ratio | 1.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
46.90 | ||||
-112.90 | ||||
-99.70 | ||||
-45.50 | ||||
-30.72 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
266.93M | ||||
3.71 | ||||
22.77 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2024 | -0.64 | -0.52 | 18.75 |
Q04 2023 | -0.43 | -0.42 | 2.33 |
Q03 2023 | -0.61 | -0.56 | 8.20 |
Q02 2023 | -0.71 | -0.66 | 7.04 |
Q01 2023 | -0.95 | -0.62 | 34.74 |
Q04 2022 | -0.45 | -0.59 | -31.11 |
Q03 2022 | -0.68 | -0.65 | 4.41 |
Q02 2022 | -0.53 | -0.67 | -26.42 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 4th Oct 2023 |
Estimated EPS Next Report | -0.56 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.25M |
Shares Outstanding | 73.63K |
Shares Float | 62.22M |
Trades Count | 12.03K |
Dollar Volume | 12.39M |
Avg. Volume | 767.23K |
Avg. Weekly Volume | 526.54K |
Avg. Monthly Volume | 783.31K |
Avg. Quarterly Volume | 991.84K |
Accolade Inc. (NASDAQ: ACCD) stock closed at 17.98 per share at the end of the most recent trading day (a -1.86% change compared to the prior day closing price) with a volume of 972.61K shares and market capitalization of 717.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 1230 people. Accolade Inc. CEO is Rajeev Singh.
The one-year performance of Accolade Inc. stock is %, while year-to-date (YTD) performance is -43.77%. ACCD stock has a five-year performance of %. Its 52-week range is between 6.83 and 17.005, which gives ACCD stock a 52-week price range ratio of 28.70%
Accolade Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.06, a price-to-sale (PS) ratio of 2.09, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -39.92%, a ROC of -43.33% and a ROE of -71.05%. The company’s profit margin is -30.72%, its EBITDA margin is -99.70%, and its revenue ttm is $266.93 Million , which makes it $3.71 revenue per share.
Of the last four earnings reports from Accolade Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.56 for the next earnings report. Accolade Inc.’s next earnings report date is 04th Oct 2023.
The consensus rating of Wall Street analysts for Accolade Inc. is Moderate Buy (1.57), with a target price of $13.63, which is +39.79% compared to the current price. The earnings rating for Accolade Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Accolade Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Accolade Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.18, ATR14 : 1.29, CCI20 : 158.09, Chaikin Money Flow : 0.02, MACD : 0.00, Money Flow Index : 63.98, ROC : 39.16, RSI : 0.00, STOCH (14,3) : 86.83, STOCH RSI : 0.00, UO : 62.70, Williams %R : -13.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Accolade Inc. in the last 12-months were: Barnes Stephen (Option Excercise at a value of $0), Barnes Stephen (Sold 6 824 shares of value $84 909 ), Barnes Stephen H. (Sold 2 576 shares of value $35 575 ), Brodsky Jeffrey (Option Excercise at a value of $0), Cavanaugh Robert (Option Excercise at a value of $0), Cavanaugh Robert (Sold 7 350 shares of value $91 111 ), Cavanaugh Robert N (Sold 2 511 shares of value $34 677 ), Colin McHugh (Sold 0 shares of value $0 ), Colin McHugh (Sold 728 shares of value $10 161 ), Eskew Richard (Sold 489 shares of value $7 024 ), Hilton Michael (Option Excercise at a value of $0), Hilton Michael (Sold 3 326 shares of value $37 419 ), Jeffrey S. Brodsky (Option Excercise at a value of $0), McHugh Colin (Sold 370 shares of value $5 315 ), Michael W. Hilton (Option Excercise at a value of $0), Michael W. Hilton (Sold 890 shares of value $8 949 ), Nabel Elizabeth (Sold 0 shares of value $0 ), Peter S. Klein (Option Excercise at a value of $0), Rajeev Singh (Option Excercise at a value of $0), Rajeev Singh (Sold 1 171 shares of value $12 216 ), Richard Eskew (Option Excercise at a value of $5 065), Richard Eskew (Sold 4 102 shares of value $51 096 ), Robert Cavanaugh (Option Excercise at a value of $0), Robert Cavanaugh (Sold 814 shares of value $8 628 ), Singh Rajeev (Option Excercise at a value of $1 829 096), Singh Rajeev (Sold 18 039 shares of value $227 458 ), Stephen Barnes (Option Excercise at a value of $0), Stephen Barnes (Sold 631 shares of value $6 699 ), Thomas J. Neff (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Moderate Buy | Moderate Buy |
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. it generates revenue through providing personalized health guidance solutions to members.
CEO: Rajeev Singh
Telephone: +1 206 926-8100
Address: 1201 Third Avenue, Seattle 98101, WA, US
Number of employees: 1 230
Wed, 27 Sep 2023 11:01 GMT Analysts Conflicted on These Healthcare Names: Accolade (ACCD), Arcturus Therapeutics (ARCT) and PDS Biotechnology (PDSB)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.